The increased cardiovascular (CV) disease risk in patients with morbid obesity (MO) cannot be fully explained by traditional CV risk factors. Activation of the receptor of Advanced Glycation Endproducts (RAGE) leads to inflammation via the NF kb (nuclear factor kb) pathway. The soluble form of RAGE (sRAGE), which is present in plasma, can bind to ligands of RAGE and avoids interaction of RAGE with proinflammatory ligands. We investigated sRAGE levels in patients with MO and compared them with healthy lean controls (CO), before and after bariatric surgery. DESIGN: We conducted a cross-sectional study and a 24-month longitudinal study. SUBJECTS: We included 85 patients (mean age: 41±12 years; mean body mass index (BMI): 45.4±7.9 kg m À 2 ) with MO in comparison with 40 CO (mean age: 42 ± 13 years; mean BMI: 26.0 ± 5.5 kg m À 2 ). All patients were investigated before and 2 years after bariatric surgery. Apart from weight and CV risk markers (blood pressure, lipids), a glucose tolerance test (75 g), renal and inflammation parameters were assessed. sRAGE levels were assessed by a commercial ELISA. To investigate the associations of the observed reductions of values, delta (D) of parameters were calculated. RESULTS: Patients with MO had significant lower sRAGE levels than CO: 1010 ± 514 vs 1501 ± 674 pg ml À 1 ; Po0.001. In the longitudinal study, sRAGE levels increased significantly after bariatric surgery from 1010±514 to 1261±710 pg ml
INTRODUCTION
Hyperglycemia leads to non-enzymatic glycation of intracellular and extracellular protein by forming advanced glycation endproducts (AGEs). 1 The RAGE (receptor of AGEs), a multi-ligand member of the immunoglobulin superfamily of transmembrane cell surface molecules, is a specific membrane-bound receptor for AGEs, 2 and activation of the RAGE by AGEs has a major role in the pathogenesis of diabetic vascular complications by way of activation of the NF kb (nuclear factor kb) pathway. 3 sRAGE is the soluble receptor of RAGE existing in the circulation. sRAGE levels have been found to be associated with chronic inflammatory diseases, including atherosclerosis and diabetes. [4] [5] [6] sRAGE acts as a decoy to prevent an interaction between AGE and RAGE and therefore an AGE-mediated damage.
sRAGE is a product of both alternative splicing of the gene for RAGE (esRAGE-endogenous secretory RAGE) and cleavage of membrane-bound RAGE. 7, 8 Up to now we know that there are a number of distinct splice variants of sRAGE. 7 Therefore, it has been suggested that esRAGE might constitute only a part, but not all of the human sRAGE in plasma. 9 To be able to measure the full amount of sRAGE, in our study we measured total sRAGE.
Studies have demonstrated the influence of RAGE on atherosclerosis as well as on diabetic complications. [4] [5] [6] Circulating serum levels of sRAGE in human subjects have been shown to be associated with a range of cardio/cerebro-vascular risk factors, including essential hypertension, 10 coronary artery disease, 6 intima-media thickening of the arteries, 11 hypercholesterolemia, 12 vascular dementia, 13 non-alcoholic fatty liver disease 14 and the diabetic state. 15 Moreover, increased sRAGE levels have been associated with extreme longevity, suggesting a role for RAGE/sRAGE in the aging process. 16 The existing data about sRAGE and cardiovascular (CV) risk are rather controversial, but there is one finding that is consistent in all studies-an inverse correlation between sRAGE levels with BMI. [17] [18] [19] [20] [21] However, up to now nearly all studies about sRAGE were done in a crosssectional setting.
comparison with non-obese control subjects, as well as the effect of weight loss induced by bariatric surgery. Besides, we investigated if sRAGE levels are associated with insulin resistance in MO patients, and the impact of bariatric surgery and weight loss on sRAGE levels.
METHODS

Protocol and subjects
The study was approved by the Institutional Ethics Committee and all subjects gave their informed consent. Patients were enlisted at the outpatients' Department for Morbid Obesity of Rudolfstiftung Hospital, Vienna.
A total of 85 patients with MO (75 women, BMI 45.4 ± 7.9 kg m À 2 ) and 40 healthy controls (CO) (30 women, BMI 26.0 ± 5.5 kg m À 2 ) were included in a cross-sectional study. Patients' characteristics are presented in Table 1 . In the longitudinal study, all MO patients were investigated before and 2 years after bariatric surgery. All patients included were on a stable weight for at least 3 months.
Surgery had been indicated according to the guidelines of the National Institutes of Health Consensus Statement for surgery in severe obesity (http://consensus.nih.gov/1991/1991gisurgeryobesity084html.htm). Patients were systematically referred to a multidisciplinary team for medical, psychological, nutritional and surgical expertise.
In addition to our previous standard exclusion criteria, 23 patients with known diabetes were excluded for the purpose of this study.
In all, 74.2% (n ¼ 63) of the patients underwent laparoscopic Roux-en-Y Gastric Bypass (RYGB), 12.9% (n ¼ 11) had a sleeve gastrectomy and 12.9% (n ¼ 11) gastric banding. All patients attended the postoperative-care follow-up program organized by the multidisciplinary team.
Medication
In the cross-sectional study cohort, 28 of 85 patients (33.3%) were on antihypertensive therapy; only two patients required a statin (2.3%).
Postoperative antihypertensive treatments and statins could be stopped in all patients.
Analyses
Anthropometric measurements were taken from all patients, dietary habits and exercise habits were assessed, as well as family history of MO and diabetes. Blood samples were taken after an overnight fast. Renal, inflammatory, liver parameter and lipids were assessed. All patients underwent a 2-h 75-g oral glucose tolerance test. Blood glucose, cholesterol, HDL (high-density lipoprotein) cholesterol and triglyceride levels were measured by enzymatic in vitro tests (Roche Diagnostics GmbH, Graz, Austria). Glycosylated hemoglobin (HbA1c) was measured by highperformance liquid chromatography (Diamat, Bio-Rad, Hercules, CA, USA). CRP was measured with a nephelometric assay in serum (Dade Behring, Marburg, Germany). sRAGE levels were evaluated by a commercial ELISA (R&D Systems Inc., Minneapolis, MN, USA). Samples were analyzed in duplicate. All ELISA kits had the same Lot number. All samples were rethawed and analyzed on the same day. In addition, all samples of individual patients were placed on the same plate. Measured Intra-and Inter-assay variability coefficients were 7.0% and 9.9%, respectively.
Calculations and statistics
Data are shown as mean ± s.d. HOMA (homeostatic model assessment)-insulin Resistance (HOMA-IR) was calculated. 24 We calculated excess weight by using the Broca formula weight minus normal weight, where normal weight is in kg ( ¼ height (in cm) À 100), as described before. Mean excess weight loss was calculated by weight loss in kg divided by normal weight Â 100. Differences were analyzed by Student's paired or unpaired t-test as appropriate. In order to investigate the associations of the observed reductions of the values, D values of parameters were calculated. Preoperative, postoperative and delta data were tested for association with each other by univariate and multiple linear regression analysis. For DsRAGE levels baseline age (at inclusion) was used in univariate and multivariate models. To identify the most important predictors, only variables that Table 1 . Clinical characteristics of patients with morbid obesity and healthy control subjects 
RESULTS
Results-cross-sectional Baseline characteristics of the patients and the CO group are demonstrated in Table 1 . sRAGE levels were significantly lower in patients with MO compared with CO: 1010 ± 514 vs 1501±674 pg ml
; Po0.001 (Figure 1 ). At baseline, patients did not differ from the CO group regarding age, blood pressure and lipids (apart from total cholesterol, which was slightly lower in the MO group). Plasma creatinine concentrations were slightly lower in MO patients. However, this difference was small and both groups were within the normal range.
Correlation analysis-cross-sectional
Correlation analysis of sRAGE levels in all patients included all available quantitative variables such as age, weight, BMI, blood pressure, lipids, fasting glucose, 2-h glucose, fasting insulin, 2-h insulin, HOMA-IR, HbA1c, creatinine, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase and gamma glutamyl transferase. Of all these variables only creatinine remained significantly correlated with sRAGE (r ¼ 0.403; P ¼ 0.001).
Results-longitudinal
Two years after bariatric surgery, weight loss by 31% of the total body weight and BMI loss by 30% were observed. Additionally, patients had a loss of excessive body weight of 59%. Risk markers such as blood pressure, glucose and insulin levels dropped dramatically, lipids and transaminases decreased distinctly (Table 1) .
sRAGES levels increased significantly after bariatric surgery from 1010 ± 514 to 1261 ± 710 pg ml À 1 ; P ¼ 0.008 (Figure 1 ).
Univariate and multivariate regression analysis-longitudinal
We performed two correlation analyses in a univariate fashion: the first one to investigate the determinants for the post-surgery sRAGE levels (Table 2) , the second one for the change (D) of sRAGE levels (Table 3) . We included all quantitative and qualitative variables available.
In the first one only insulin 1-h postprandial correlated with post-surgery sRAGE levels (r ¼ 0.349; P ¼ 0.017) was analysed. Therefore, Insulin 1-h postprandial was the single most independent predictor for post-surgery sRAGE levels.
In the second analysis we found DsRAGE levels correlated with:
In a multivariate regression analysis, we included all variables that were significantly associated with DsRAGE in univariate fashion. After a stepwise backward analysis, glucose 1-h postprandial (beta ¼ À 0.227; P ¼ 0.027), Dglucose 2-h postprandial (beta ¼ À 0.303; P ¼ 0.027), Dinsulin 2-h postprandial (beta ¼ À 0.597; P ¼ 0.005) and DHOMA-IR (beta ¼ À 0.418; P ¼ 0.019) remained in the final model as predictors for DsRAGE. In other words, these four estimates of insulin resistance explained 67.5% of the variance of observed DsRAGE levels.
As expected in a confounding analysis, the variables confounded each other. Therefore all four remained as most independent predictors for sRAGE.
DISCUSSION
To the best of our knowledge this is the first study investigating sRAGE levels in patients with MO undergoing bariatric surgery. Our study showed significantly lower sRAGE levels in MO patients compared with CO. Additionally, we demonstrated a significant increase of sRAGE levels after the dramatic weight loss induced by bariatric surgery. DsRAGE levels correlated negatively with insulin resistance. In addition, in contrast to many other studies, we were able to demonstrate sRAGE levels in a longitudinal course.
AGEs are generated as a result of enhanced oxidative stress and chronic hyperglycemia. AGEs can interact with receptors such as RAGE, and induce inflammation and oxidative stress in particular through the NFkb pathway. All these effects lead to Figure 1 . Serum concentrations of sRAGE levels in morbid obese patients before (n ¼ 85) and after (n ¼ 85) bariatric surgery compared with healthy controls (n ¼ 40). accelerated atherosclerosis. 26 RAGE exists in several variants. sRAGE is a C-truncated variant of RAGE, a 50-kDa protein, and is mainly produced by splicing or cleavage from cell surface through metalloproteinases in endothelial cells. 27 Norata et al. 17 showed an association between sRAGE levels and BMI as well as waist/hip ratio in a general population. In this study, only patients without CV diseases and diabetes were included and the authors could demonstrate an inverse correlation between sRAGE levels and factors of the metabolic syndrome such as BMI, waist/hip ratio and fasting glucose in 176 subjects. There are other studies depicting a link between BMI, waist circumference and sRAGE, but those are cross-sectional studies that are in contrast to our study. 18, 19 Interestingly, in the large CARDS trial, 20 patients with lower BMI levels had higher levels of sRAGE, which is in line with our longitudinal data demonstrating that sRAGE levels increase after weight loss. sRAGE acts as a decoy to protect one from AGE-mediated damage. Animal studies have proven that the administration of sRAGE stabilized established atherosclerosis. 28 Falcone et al. 6 demonstrated in their study that sRAGE levels are lower in non-diabetic men with coronary artery disease than in those without the disease. In addition, the authors of the Dallas Heart Study could show in a subset of patients an inverse correlation of sRAGE levels with coronary artery calcium. 4 These data are of interest for the observation in our study where MO patients have significantly lower sRAGE levels than healthy CO. Basta et al. 29 found an inverse association between sRAGE levels and intima-media thickness in 142 patients with chronic kidney disease. These data are in line with those of Chiang et al., 30 who showed that enhanced plasma levels of sRAGE were associated with better major adverse CV event-free survival in 180 nondiabetic patients.
Several studies have shown that low levels of sRAGE may be not only predictive of not only of stroke risk, 31, 32 but also associated with subclinical cerebrovascular disease, particularly in ethnic groups with increased risk for cerebrovascular disease. 33 In the recent analysis of the CARDS study, 20 the hazard ratio for sRAGE and stroke was 0.66, but it did not reach levels of significance owing to the relatively low number (n ¼ 44) of stroke events. Remarkably, in that study RAGE levels were identical in cases and CO subjects for CV diseases. 20 However, when coronary heart disease was considered separately, sRAGE levels were higher in cases than in control subjects adjusted for age and sex. There are additional controversial results regarding sRAGE levels in atherosclerosis. Nin et al. 34 showed in a cross-sectional study that sRAGE levels are higher in type 1 diabetic patients with CV diseases than in those without the disease; Humpert et al. It is interesting that drugs that influence the risk of atherosclerosis or insulin resistance showed higher sRAGE levels associated with these treatments. 35, 36 Tam et al. 35 have demonstrated that sRAGE levels were higher in patients treated with atorvastatin in comparison with those who did not receive lipid-lowering drugs. In our study we can exclude such an interference as no patient was on Atorvastatin treatment. Only two patients received simvastatin, which was stopped after surgery.
In another study, Tan et al. 36 have shown that treating type 2 diabetic patients with thiazolidinedione can increase circulating sRAGE levels. As both the treatment with thiazolidinediones and bariatric surgery decrease insulin resistance-as confirmed in the present study (see Table 1 )-one might speculate that lowering insulin resistance could lead to the increase in sRAGE levels, as demonstrated in our study.
Obesity as a cancer risk factor has become more and more important during the last few years. In 2009 Adams et al. 37 could demonstrate in a large study over a mean follow-up period of 12.5 years a significantly lower incidence of cancer in patients after gastric bypass surgery compared with severely obese CO without surgery. In addition, cancer mortality was 46% lower in the surgery group. In the Swedish Obesity Study, bariatric surgery was associated with a reduced cancer incidence in women. 38 Recently Jiao et al. 39 reported an inverse correlation between sRAGE and pancreatic cancer, suggesting a protective effect of sRAGE regarding RAGE-mediated damage. In our study we could demonstrate an increase of sRAGE after bariatric surgery. Therefore, our results might contribute to explain the reduced cancer incidence and mortality after bariatric surgery.
In our study we decided to measure the total sRAGE. Several other studies have also measured the endogenous secretory RAGE, which is one of the splice variants that directs the synthesis of RAGE proteins carrying all the extracellular domains but lacks the transmembrane and intracytoplasmic domains. 40 Several studies have shown a link between esRAGE and atherosclerosis and the metabolic syndrome. 11, 41 However, esRAGE is only one of the splice variants of sRAGE. Koyama et al. 41 proposed that the mean plasma esRAGE level is approximately one-fifth of the total sRAGE level in healthy individuals.
One limitation of our study is that we could not include as many men as women. However, our gender distribution reflects the reallife situation in our obesity outpatient clinic and is similar to many other obesity studies. 42 In conclusion, our study shows significantly lower levels of sRAGE in patients with MO compared with healthy CO. The lower sRAGE levels in MO patients could be a further explanation for the higher risk of CV disease and cancer in those patients. In addition, sRAGE levels rise significantly after a dramatic weight reductioninduced bariatric surgery, which might be linked to the much lower insulin resistance after bariatric surgery. This rise could be another beneficial effect of bariatric surgery. Further studies are needed to investigate the relationship between sRAGE levels and cancer.
